Related Experiment Video
Updated: Jul 2, 2026
06:19
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis
Mauro Zaffaroni1, Annalisa Rizzo, Silvana Maria Baldini
1Centro Studi Sclerosi Multipla, Gallarate, Italy. mauro.zaffaroni@aogallarate.it
Summary
Mitoxantrone (MX) effectively reduced relapses and disability in early multiple sclerosis (MS) when used as induction therapy. However, MX showed limited efficacy for advanced MS requiring rescue therapy.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Pharmacology
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Interferon-beta (IFN-beta) is a common treatment, but some patients require more aggressive therapies.
- Mitoxantrone (MX) is an immunomodulatory agent used in certain MS cases.
Purpose of the Study:
- To evaluate the efficacy of mitoxantrone (MX) in multiple sclerosis (MS) patients based on treatment context.
- To compare MX effectiveness in induction, add-on/combination, and rescue therapy settings for MS.
Main Methods:
- Retrospective analysis of data from 70 multiple sclerosis (MS) patients.
- Patients received mitoxantrone (MX) before or in combination with Interferon-beta (IFN-beta).
- Treatment groups included induction, add-on/combination, and rescue therapy.
Main Results:
- Significant reduction in relapse rate and disability observed with MX induction therapy.
- Mitoxantrone (MX) was ineffective as rescue therapy for advanced MS.
- Add-on/combination therapy outcomes were not explicitly detailed but implied less efficacy than induction.
Conclusions:
- Mitoxantrone (MX) serves as a valid induction therapy option for aggressive or active early-stage multiple sclerosis (MS).
- MX is not effective for managing advanced MS or secondary progression when used as rescue therapy.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...